Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home
Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home
Quercetin is a flavonoid dietary supplement that occurs in many edible fruits and vegetables.
 It has remarkable antioxidant, anti-inflammatory, immunoprotective and antiviral properties.
 It is widely used to boost the body immune system against infections and keeping healthy
 life-style. The purpose of the present study is to investigate the potential benefits of
 quercetin for preventing COVID-19 disease progression and symptoms improvement in the early
 stage of infection.
The strong antioxidant and anti-inflammatory properties of quercetin are closely related to
 its effective fight against a variety of disease conditions related to inflammation,
 including: viral infections, allergies, asthma, hay fever, arthritis, respiratory diseases,
 "hardening of the arteries" (atherosclerosis), high cholesterol, heart disease and
 circulation problems, insulin resistance and diabetes, eye-related disorders, including
 cataracts, stomach ulcers, cognitive impairment, gout, cancer, chronic fatigue syndrome,
 inflammation of the prostate, bladder, and ovaries, chronic infections of the prostate, skin
 disorders, including dermatitis and hives. Quercetin can help stop damaging particles in the
 body known as free radicals, which damages the cells by natural oxidation processes. It can
 also reduce the expression of inflammatory genes in the cells.

 Quercetin has been shown to be effective against broad range of viruses including human
 respiratory syncytial virus (hRSV), rhinovirus, echovirus, coxsackievirus, poliovirus,
 parainfluenza type 3, Herpes Simplex Virus-1, cytomegalovirus, SARS-CoV-1, dengue virus, and
 Hepatitis C virus.

 The purpose of the present study is to investigate the potential benefits of quercetin for
 preventing COVID-19 disease progression and improving symptoms in the early stage of
 infection.
Inclusion Criteria:

 -  Patients must be 18 years of age or older, of either gender

 -  Patients must be tested positive for SARS-CoV-2 by RT-PCR

 -  Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever,
 fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of
 breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss
 of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular
 pain etc.

 -  Patients must be in the early stage of COVID-19 disease who do not require
 hospitalisation at the time of screening

 -  Patients must be under the care of a Physician for diagnosis of COVID-19

 -  Patients who have signed informed consent

 Exclusion Criteria:

 -  Patients with proven hypersensitivity or allergic reaction to quercetin

 -  Patients with known chronic kidney disease with estimated creatinine clearance < 50
 mL/minute or need for dialysis

 -  Patients who are severely hypotensive defined as needing hemodynamic pressors to
 maintain blood pressure

 -  Patients with moderate or severe thrombocytopenia (platelet count <100 × 10⁹/L);

 -  Pregnant patients

 -  Patients declining to participate